Abstract P3-10-05: Phase III trial evaluating paclitaxel plus carboplatin versus paclitaxel plus epirubicin as first-line treatment for metastatic breast cancer

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer

Bone Marrow Transplantation ◽

10.1038/sj.bmt.1705935 ◽

2007 ◽

Vol 41 (6) ◽

pp. 555-562 ◽

Cited By ~ 24

Author(s):

P Biron ◽

M Durand ◽

H Roché ◽

T Delozier ◽

C Battista ◽

...

Keyword(s):

Breast Cancer ◽

Stem Cell ◽

Metastatic Breast ◽

Phase Iii ◽

High Dose ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

Phase III trial comparing epirubicin/paclitaxel vs epirubicin/cyclophosphamid as first line treatment in metastatic breast cancer: Preliminary results of a German AGO trial

European Journal of Cancer ◽

10.1016/s0959-8049(98)80364-x ◽

1998 ◽

Vol 34 ◽

pp. S90 ◽

Cited By ~ 1

Author(s):

G. von Minckwitz ◽

W. Kuhn ◽

C. Thomssen ◽

M. Untch ◽

Th. Bauknecht ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

Preliminary Results ◽

Clinical Benefit Rate and Time to Response in RIBBON-1, a Randomized, Double-Blind, Phase III Trial of Chemotherapy with or without Bevacizumab (B) for the First-Line Treatment of HER2-Negative Locally Recurrent or Metastatic Breast Cancer (MBC).

10.1158/0008-5472.sabcs-09-6084 ◽

2009 ◽

Cited By ~ 4

Author(s):

N. Robert ◽

V. Dieras ◽

J. Glaspy ◽

A. Brufsky ◽

I. Bondarenko ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Double Blind ◽

Phase Iii Trial ◽

Locally Recurrent ◽

A multicenter randomized phase III trial of nonpegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide (MC) versus liposome-encapsulated doxorubicin citrate plus vinorelbine (MV) as first-line treatment in locally advanced (LABC) or metastatic breast cancer (MBC).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.1041 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 1041-1041

Author(s):

V. Lorusso ◽

F. Giotta ◽

R. Bordonaro ◽

E. Maiello ◽

S. Del Prete ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

5016 Efficacy in patient subgroups in RIBBON-1, a randomized, double-blind, Phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)70908-5 ◽

2009 ◽

Vol 7 (2) ◽

pp. 265 ◽

Cited By ~ 15

Author(s):

V. Dieras ◽

J. Glaspy ◽

A. Brufsky ◽

I. Bondarenko ◽

O. Lipatov ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Double Blind ◽

Phase Iii Trial ◽

Locally Recurrent ◽

Patient Subgroups ◽

Phase III study of liposome-encapsulated doxorubicin (TLC D-99) and cyclophosphamide (CPA) vs. epirubicin (EPI) and CPA in first-line treatment of metastatic breast cancer (MBC)

European Journal of Cancer ◽

10.1016/s0959-8049(99)81679-7 ◽

1999 ◽

Vol 35 ◽

pp. S315 ◽

Cited By ~ 2

Author(s):

S. Chan ◽

N. Davidson ◽

E. Juozaityte ◽

F. Erdkamp ◽

L. Hooftman ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Study ◽

Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel (D2) for First-Line Treatment of Metastatic Breast Cancer

Oncology ◽

10.1159/000320640 ◽

2010 ◽

Vol 79 (3-4) ◽

pp. 197-203 ◽

Cited By ~ 11

Author(s):

Hans-Joachim Stemmler ◽

Nadia Harbeck ◽

Isolde Gröll de Rivera ◽

Ursula Vehling Kaiser ◽

Gerhard Rauthe ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Study ◽

Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC

Anti-Cancer Drugs ◽

10.1097/01.cad.0000175587.31940.19 ◽

2005 ◽

Vol 16 (8) ◽

pp. 871-877 ◽

Cited By ~ 44

Author(s):

G. von Minckwitz ◽

I. Chernozemsky ◽

L. Sirakova ◽

P. Chilingirov ◽

R. Souchon ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Progression Free Survival ◽

Multicenter Trial ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Free Survival ◽

Abstract CT212: A phase III randomized study of paclitaxel (T) and trastuzumab (H) versus T, H and lapatinib (L) in first line treatment of HER2+ metastatic breast cancer (MBC)

10.1158/1538-7445.am2020-ct212 ◽

2020 ◽

Author(s):

John Crown ◽

William Jacot ◽

Denis M. Collins ◽

Linda Coate ◽

Anna Saetersdal ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Study ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Faculty Opinions recommendation of Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1128881.585979 ◽

2008 ◽

Author(s):

Carmelo Bengala

Keyword(s):

Breast Cancer ◽

Randomized Study ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Double Blind ◽